Dermatol. praxi. 2024;18(1):44-47 | DOI: 10.36290/der.2024.007

Bimekizumab in patient with psoriasis and psoriatic arthritis

MUDr. Marie Jandová, Ph.D.
Klinika nemocí kožních a pohlavních, FN a LF UK v Hradci Králové

We present a case report of a 69-year-old female patient with psoriasis and psoriatic arthritis, who has been treated with several biological agents since 2007. Currently, she is taking bimekizumab with excellent efficacy on skin manifestations, but with inadequate effect on joint issues.

Keywords: psoriasis, psoriatic arthritis.

Accepted: March 26, 2024; Published: April 3, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jandová M. Bimekizumab in patient with psoriasis and psoriatic arthritis. Dermatol. praxi. 2024;18(1):44-47. doi: 10.36290/der.2024.007.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zhou X, Chen Y, Cui L, Shi Y, et al. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 2022;13(1):81. doi: 10.1038/s41419-022-04523-3. PMID: 35075118; PMCID: PMC8786887. Go to original source... Go to PubMed...
    2. SmPC Bimzelx. Available from: www.sukl.cz.
    3. Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multi­centre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2. Erratum in: Lancet. 2021;397(10275):670. PMID: 33549193. Go to original source... Go to PubMed...
    4. Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus Adalimumab in Plaque Psoriasis. N Engl J Med. 2021;385(2):130-141. doi: 10.1056/NEJMoa2102388. Epub 2021 Apr 23. PMID: 33891379. Go to original source... Go to PubMed...
    5. Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475-486. doi: 10.1016/S0140-6736(21)00126-4. Erratum in: Lancet. 2021;397(10280):1182. PMID: 33549192. Go to original source... Go to PubMed...
    6. Reich K. Presented at EADV 2021;poster P1404.

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.